Publications

Hayes Publications are available through the Hayes Knowledge Center, a portal to world-class research and unbiased analyses on the clinical, financial, and risk impacts of emerging, controversial, and disruptive healthcare technologies.

Every Hayes publication is developed by multidisciplinary teams of clinicians and scientists using rigorous methods grounded in internally recognized standards for systematic review and Health Technology Assessment. Learn more about these evidence resources and see sample titles below.

See below for some of our recent publications.

Trodelvy (sacituzumab govitecan-hziy) for Metastatic Triple Negative Breast Cancer

Trodelvy (sacituzumab govitecan-hziy) is an intravenously administered antibody-drug conjugate (ADC) indicated for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least 2 prior therapies for metastatic disease. Trodelvy is the first FDA-approved ADC indicated for the treatment of TNBC.

Botulinum Toxin for Treatment of Raynaud Phenomenon

Focus of the Report: For use of botulinum toxin (BTX) for Raynaud phenomenon (RP).

Technology Description: BTX has been investigated as a treatment for various chronic painful conditions because of its potential to reduce muscle tension and modulate pain receptor activity in the central nervous system. For the treatment of RP, there is currently no sta…

Reblozyl (Luspatercept) for Beta Thalassemia

Reblozyl is an erythroid maturation agent administered via subcutaneous injection indicated for the treatment of patients with transfusion-dependent beta thalassemia. This recombinant fusion protein is believed to help immature cells develop into red blood cells, thereby preventing anemia and reducing or eliminating the need for frequent blood transfusions.

Lopinavir/Ritonavir for COVID-19

Lopinavir/ritonavir is an oral antiretroviral protease inhibitor combination agent under investigation for the treatment of COVID-19. Lopinavir/ritonavir is FDA approved for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients aged 14 days and older.

Convalescent Plasma for Treatment of COVID-19

Convalescent plasma is a form of passive antibody therapy that is under investigation for the treatment of COVID-19. Convalescent plasma is collected from patients who have recovered from COVID-19 and administered to patients with active, symptomatic disease via intravenous infusion.

Magnetic Resonance Elastography for Prognosis of Liver Disease Progression

Focus of the Report: Magnetic resonance elastography (MRE) is a diagnostic test for assessing hepatic fibrosis, a form of liver damage that occurs when healthy tissue is replaced by stiff, fibrous scar tissue. This report focuses on MRE for prediction of serious potential consequences of liver disease such as development of cirrhosis or liver…